None listed
Conditions
Interventions
L-454560 Type of group
15 mg of L-454560 will be administered with placebo in adult patients with chronic asthma.
Sponsors
MERCK SHARP & DOHME PERU S.R.L.,
Eligibility
Inclusion criteria
Inclusion criteria: The patient understands the study procedures and agrees to participate as indicated by signing the appropriate Informed Consent Document. The patient has a medical history (of at least one year) consistent with persistent or intermittent asthma symptoms that include, but are not limited to; dyspnea, wheezing, tightness in the chest, cough and sputum production. The patient has a FEVi, while not using p-agonists for six hours, between 50% and 80% of the predicted value, documented at least twice during Visits 1, 2, and / or 3.
Exclusion criteria
Exclusion criteria: In the opinion of the investigator, the patient is mentally or legally incapacitated, which prevents the informed consent from being obtained; He is unable to read. The patient shows significant abnormalities in the physical examination of Visit 1 or in laboratory measurements. The patient has a recent history (within 3 months of Visit 1) of a clinically symptomatic psychiatric disorder.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:FEV1 Measure:The FEV1 measured at the end of the interval of a daily dose. Timepoints:14 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:not contemplated Measure:not contemplated Timepoints:not contemplated | — |
Countries
Australia, Brazil, Colombia, Hungary, Israel, United States
Contacts
Public ContactStela Lopez
MERCK SHARP & DOHME PERU S.R.L
Outcome results
None listed